Intellia Therapeutics - NTLA Stock Forecast, Price & News

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTLA shares.
View NTLA analyst ratings or view top-rated stocks.

18 brokers have issued 12 month price targets for Intellia Therapeutics' stock. Their NTLA share price forecasts range from $39.00 to $180.00. On average, they predict the company's stock price to reach $87.18 in the next year. This suggests a possible upside of 135.0% from the stock's current price.
View analysts price targets for NTLA or view top-rated stocks among Wall Street analysts.

Intellia Therapeutics' stock was trading at $34.89 on January 1st, 2023. Since then, NTLA stock has increased by 6.3% and is now trading at $37.09.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our NTLA earnings forecast.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its earnings results on Thursday, February, 23rd. The company reported ($1.40) EPS for the quarter, meeting the consensus estimate of ($1.40). The company earned $13.60 million during the quarter, compared to analyst estimates of $10.71 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 48.70% and a negative net margin of 909.78%. The company's revenue for the quarter was up 5.4% on a year-over-year basis. During the same period last year, the company posted ($1.09) EPS.

ETFs with the largest weight of Intellia Therapeutics (NASDAQ:NTLA) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion mRNA ETF (MSGR), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Moonshot Innovators ETF (MOON) and Franklin Genomic Advancements ETF (HELX).

12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

(NTLA) raised $85 million in an initial public offering on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Intellia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.97%), Sumitomo Mitsui Trust Holdings Inc. (3.78%), Nikko Asset Management Americas Inc. (3.78%), Morgan Stanley (3.20%), Price T Rowe Associates Inc. MD (2.45%) and Alliancebernstein L.P. (2.15%). Insiders that own company stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends.

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTLA stock can currently be purchased for approximately $37.09.

Intellia Therapeutics (NASDAQ:NTLA) has a market capitalization of $3.26 billion and generates $52.12 million in revenue each year. The company earns $-474,190,000.00 in net income (profit) each year or ($6.18) on an earnings per share basis.

The company employs 485 workers across the globe.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The official website for the company is www.intelliatx.com. The company can be reached via phone at (857) 285-6200 or via email at lina.li@intelliatx.com.